Analyst Ratings For Halozyme Therapeutics (NASDAQ:HALO)
Today, BMO Capital Markets raised its price target on Halozyme Therapeutics (NASDAQ:HALO) to $19.00 per share.
Some recent analyst ratings include
- 1/24/2018-Goldman Sachs Group initiated coverage with a Neutral rating.
- 11/22/2017-Barclays was Downgraded by analysts at Barclays from a “Overweight ” rating to a ” Hold” rating. They now have a $19.00 price target on the stock, up previously from $16.00 .
Recent Insider Trading Activity For Halozyme Therapeutics (NASDAQ:HALO)
Halozyme Therapeutics (NASDAQ:HALO) has insider ownership of 16.80% and institutional ownership of 81.56%.
- On 8/20/2015 Laurie Stelzer, CFO, bought 10,000 with an average share price of $17.24 per share and the total transaction amounting to $172,400.00.
- On 6/18/2015 Kenneth J Kelley, Director, sold 20,000 with an average share price of $21.00 per share and the total transaction amounting to $420,000.00.
- On 9/16/2014 David A Ramsay, CFO, bought 25,000 with an average share price of $8.90 per share and the total transaction amounting to $222,500.00.
- On 9/16/2014 Helen Torley, CEO, bought 50,000 with an average share price of $8.92 per share and the total transaction amounting to $446,000.00.
- On 8/19/2014 John Stuart Patton, Director, sold 75,000 with an average share price of $9.96 per share and the total transaction amounting to $747,000.00.
- On 5/15/2014 Robert Engler, Director, sold 126,700 with an average share price of $7.56 per share and the total transaction amounting to $957,852.00.
- On 9/16/2013 John Stuart Patton, Director, sold 75,000 with an average share price of $9.13 per share and the total transaction amounting to $684,750.00.
Recent Trading Activity for Halozyme Therapeutics (NASDAQ:HALO)
Shares of Halozyme Therapeutics closed the previous trading session at 19.79 up +0.55 2.86% with 19.520000457763672 shares trading hands.